Basket Designs: Statistical Considerations for Oncology Trials

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2022 Feb 1

PMID 35100726

Authors

Alexander M Kaizer

Joseph S Koopmeiners

Michael J Kane

Satrajit Roychoudhury

David S Hong

Brian P Hobbs

Affiliations

Soon will be listed here.

Abstract

Progress in the areas of genomics, disease pathways, and drug discovery has advanced into clinical and translational cancer research. The latest innovations in clinical trials have followed with master protocols, which are defined by inclusive eligibility criteria and devised to interrogate multiple therapies for a given tumor histology and/or multiple histologies for a given therapy under one protocol. The use of master protocols for oncology has become more common with the desire to improve the efficiency of clinical research and accelerate overall drug development. Basket trials have been devised to ascertain the extent to which a treatment strategy offers benefit to various patient subpopulations defined by a common molecular target. Conventionally conducted within the phase II setting, basket designs have become popular as drug developers seek to effectively evaluate and identify preliminary efficacy signals among clinical indications identified as promising in preclinical study. This article reviews basket trial designs in oncology settings and discusses several issues that arise with their design and analysis.

Citing Articles

Reinforced Borrowing Framework: Leveraging Auxiliary Data for Individualized Inference.

Ji Z, Wolfson J Stat Med. 2024; 43(30):5837-5848.

PMID: 39556882 PMC: 11639645. DOI: 10.1002/sim.10267.

Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development.

Thein K, Myat Y, Park B, Panigrahi K, Kummar S Cancers (Basel). 2024; 16(14).

PMID: 39061168 PMC: 11274498. DOI: 10.3390/cancers16142529.

Basket Trials: Past, Present, and Future.

Murciano-Goroff Y, Uppal M, Chen M, Harada G, Schram A Annu Rev Cancer Biol. 2024; 8(1):59-80.

PMID: 38938274 PMC: 11210107. DOI: 10.1146/annurev-cancerbio-061421-012927.

Bayesian Methods for Information Borrowing in Basket Trials: An Overview.

Zhou T, Ji Y Cancers (Basel). 2024; 16(2).

PMID: 38254740 PMC: 10813856. DOI: 10.3390/cancers16020251.

Recent innovations in adaptive trial designs: A review of design opportunities in translational research.

Kaizer A, Belli H, Ma Z, Nicklawsky A, Roberts S, Wild J J Clin Transl Sci. 2023; 7(1):e125.

PMID: 37313381 PMC: 10260347. DOI: 10.1017/cts.2023.537.

References

Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J . Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707-14. PMC: 3724515. DOI: 10.1056/NEJMoa1112302. View

Trippa L, Alexander B . Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials. J Clin Oncol. 2017; 35(6):681-687. DOI: 10.1200/JCO.2016.68.2864. View

Freidlin B, Korn E . Borrowing information across subgroups in phase II trials: is it useful?. Clin Cancer Res. 2013; 19(6):1326-34. PMC: 11388725. DOI: 10.1158/1078-0432.CCR-12-1223. View

Redig A, Janne P . Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol. 2015; 33(9):975-7. DOI: 10.1200/JCO.2014.59.8433. View

Stallard N, Todd S, Parashar D, Kimani P, Renfro L . On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. Ann Oncol. 2019; 30(4):506-509. PMC: 6503623. DOI: 10.1093/annonc/mdz038. View

Tang C, Hobbs B, Amer A, Li X, Behrens C, Rodriguez Canales J . Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep. 2018; 8(1):1922. PMC: 5792427. DOI: 10.1038/s41598-018-20471-5. View

Schram A, Reales D, Galle J, Cambria R, Durany R, Feldman D . Oncologist use and perception of large panel next-generation tumor sequencing. Ann Oncol. 2017; 28(9):2298-2304. PMC: 5834089. DOI: 10.1093/annonc/mdx294. View

Simon R . New designs for basket clinical trials in oncology. J Biopharm Stat. 2017; 28(2):245-255. DOI: 10.1080/10543406.2017.1372779. View

Chen N, Lee J . Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes. Biom J. 2018; 61(5):1219-1231. PMC: 6546564. DOI: 10.1002/bimj.201700275. View

10.

Li X, Guindani M, Ng C, Hobbs B . Spatial Bayesian modeling of GLCM with application to malignant lesion characterization. J Appl Stat. 2019; 46(2):230-246. PMC: 6706247. DOI: 10.1080/02664763.2018.1473348. View

11.

Hobbs B, Kane M, Hong D, Landin R . Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study. Ann Oncol. 2018; 29(12):2296-2301. PMC: 6311949. DOI: 10.1093/annonc/mdy457. View

12.

Trusheim M, Shrier A, Antonijevic Z, Beckman R, Campbell R, Chen C . PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. Clin Pharmacol Ther. 2016; 100(6):713-729. PMC: 5142736. DOI: 10.1002/cpt.514. View

13.

. First Tissue-Agnostic Drug Approval Issued. Cancer Discov. 2017; 7(7):656. DOI: 10.1158/2159-8290.CD-NB2017-078. View

14.

Renovanz M, Kim E . Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. Front Oncol. 2014; 4:142. PMC: 4050363. DOI: 10.3389/fonc.2014.00142. View

15.

Heinrich M, Joensuu H, Demetri G, Corless C, Apperley J, Fletcher J . Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008; 14(9):2717-25. DOI: 10.1158/1078-0432.CCR-07-4575. View

16.

Woodcock J, LaVange L . Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017; 377(1):62-70. DOI: 10.1056/NEJMra1510062. View

17.

Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R . Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015; 33(9):1000-7. PMC: 4356709. DOI: 10.1200/JCO.2014.58.2007. View

18.

Beckman R, Antonijevic Z, Kalamegham R, Chen C . Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker. Clin Pharmacol Ther. 2016; 100(6):617-625. DOI: 10.1002/cpt.446. View

19.

Drilon A, Laetsch T, Kummar S, Dubois S, Lassen U, Demetri G . Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018; 378(8):731-739. PMC: 5857389. DOI: 10.1056/NEJMoa1714448. View

20.

Yu W, Tang C, Hobbs B, Li X, Koay E, Wistuba I . Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017; 102(4):1090-1097. DOI: 10.1016/j.ijrobp.2017.10.046. View